Skip to main content
Log in

Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?

  • Letter to the Editors
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Badagliacca R, Pezzuto B, Poscia R, Mancone M, Papa S, Marcon S, Valli G, Sardella G, Ferrante F, Iacoboni C, Parola D, Fedele F, Vizza CD (2012) Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant 31:364–372

    Article  PubMed  Google Scholar 

  2. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

    Article  PubMed  CAS  Google Scholar 

  3. Nuding S, Ebelt H, Hoke RS, Krummenerl A, Wienke A, Müller-Werdan U, Werdan K (2011) Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I(f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial. Clin Res Cardiol. 100:915–923

    Article  PubMed  CAS  Google Scholar 

  4. De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, Tritapepe L (2012) Ivabradine: potential clinical applications in critically ill patients Clin Res Cardiol (2012 Oct 14 Epub ahead of print)

  5. Zhang R, Bobylev D, Stiefel P, Haverich A, Bara C (2012) Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol. 101:631–636

    Article  PubMed  CAS  Google Scholar 

  6. Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L (2010) Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 99:853–855

    Article  PubMed  Google Scholar 

  7. Correale M, Montrone D, Di Biase M, Brunetti ND (2012) Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension. Clinic Res Cardiol. 101:593–594

    Article  Google Scholar 

  8. Correale M, Montrone D, Ieva R, Di Biase M, Brunetti ND (2012) Ivabradine in systemic sclerosis related pulmonary arterial hypertension. Eur J Intern Med (2012 Sep 25 Epub ahead of print)

  9. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A (2012) Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 5:97–105

    Article  PubMed  Google Scholar 

  10. Akhmetzianova ÉK, Gaĭnitdinova VV, Bakirov AB, Bogoroditskaia OA, Timershina IR (2012) Effect of ivabradine on pulmonary hypertension in chronic obstructive pulmonary disease. Kardiologiia. 52:41–46

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michele Correale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Correale, M., Montrone, D., Ieva, R. et al. Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?. Clin Res Cardiol 102, 391–393 (2013). https://doi.org/10.1007/s00392-013-0541-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-013-0541-x

Keywords

Navigation